CKS Advisors is pleased to announce that Agilis Consulting Group (“Agilis”) has been
acquired by Kymanox Corporation (“Kymanox”).
Agilis is a trusted human factors partner for the global medical market. They specialize in helping new and established companies achieve successful human factors submissions while navigating the complex global regulatory landscape, resulting in safe and effective medical products being brought to market. The acquisition of Agilis by Kymanox helps both companies realize their shared corporate goal of bringing modern medicines to patients, while bolstering service capabilities by providing a broader array of highly specialized services to clients. Agilis’ CEO and Founder Patricia Patterson had these comments “I found CKS and Mark Young after asking other trusted small business professionals who they would recommend. Mark’s name came up repeatedly as someone who knows this business and works tirelessly for the sellers he represents. The process is intense, and I can’t imagine going through the sale of my company– which ended so successfully– without Mark and his resources at CKS.”
CKS Advisors served as the exclusive financial advisor to Agilis.
About Agilis Consulting Group:
Agilis Consulting Group is your trusted human factors partner for the global medical market. We enable product realization through successful human factors submissions while navigating the complex global regulatory landscape, resulting in safe and effective medical devices and combination products. Agilis’ proven human factors strategies, process and expertise drive regulatory success and speed to market – the first time. To learn how Agilis can support your medical device or combination product human factors success, contact email@example.com, or visit https://www.agilisconsulting.com/.
Kymanox has proven, collaborative, end-to-end solutions that help bring Life Science products to the market – and keep them there. We are a professional services organization that offers engineering, scientific, project management, quality, regulatory, human factors, testing/QC, and CQV support to companies exclusively in the biotechnology, pharmaceutical, medical device, and combination product industries. With our diverse team of experts, Kymanox helps clients navigate commercialization challenges that arise throughout a product’s life cycle – from early development to post-market – with optimized safety, quality, efficacy, and accessibility. We strive to advance Life Science Innovation Through Insightful Solutions & Collaboration. Kymanox was founded in 2004 and is headquartered in Morrisville, North Carolina USA. Kymanox is backed by WestView Capital Partners, a Boston-based growth equity firm. For more information, visit https://www.kymanox.com/.
The Principals of CKS Advisors, LLC are registered representatives of BA Securities, LLC. Securities and Investment Banking Services are offered through BA Securities, LLC Member FINRA, SIPC. CKS Advisors, LLC and BA Securities, LLC are separate and unaffiliated entities.